Syn-Med-Chemist-"Quintessential Synthetic Chemistry"---A Synthetic Chemist's Perception......
Thursday, September 18, 2014
Thursday, September 11, 2014
Now, women experiencing morning sickness can benefit from Diclegis drug
Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. Many turn to conservative management such as diet and lifestyle changes, however if this does not provide relief, women should speak with their healthcare professional about prescription treatment options.
Diclegis (see structure) is the only FDA-approved prescription NVP treatment for women who do not respond to conservative management. Approved in April 2013, the FDA granted Diclegis Pregnancy Category A status, its highest rating.
Duchesnay USA, the maker of Diclegis, is dedicated to providing pregnant women with safe and effective pharmacological treatments.
Tuesday, September 9, 2014
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D). Actavis' NDA for eluxadoline has been granted priority review status by the FDA.
Thursday, September 1, 2011
Wednesday, August 31, 2011
New cough suppressant from cocoa
Researchers are carrying out the final stages of clinical trials of a drug that contains theobromine (see structure), an ingredient found in chocolate and cocoa. The drug could be in the market in another two years.
Subscribe to:
Posts (Atom)